Free Trial
NASDAQ:IMA

ImageneBio Q2 2026 Earnings Results & Report

ImageneBio logo
$4.18 -0.06 (-1.39%)
As of 09:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ImageneBio beat analyst earnings expectations in its Q2 2026 results, released August 5, 2026. The company reported EPS of -$0.63 versus the -$0.90 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

ImageneBio EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Q2 2026 Earnings FAQ

ImageneBio (NASDAQ:IMA) reported earnings of -$0.63 per share for Q2 2026, beating the consensus estimate of -$0.90. The report was announced on Wednesday, August 5, 2026.

ImageneBio Earnings Headlines

Rent out your stocks?
If you owned a rental house, you would collect rent while you waited for it to rise in value. A covered call lets you do something similar with stocks you already own. Own at least 100 shares and you can get paid cash today for agreeing to sell them at a higher price later. That cash is yours to keep no matter what happens next. Bill Poulos breaks it down in The Retirement Paycheck Playbook, normally $29.97, free today.tc pixel
ImageneBio Corporate Event Calendar | NASDAQ:IMA
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA) is a biotechnology company focused on developing molecular diagnostic technologies for precision oncology. The company aims to generate actionable information about cancer biology from blood-based samples, supporting more informed treatment decisions and disease monitoring.

ImageneBio’s platform is designed to analyze tumor-derived molecular signals and may support applications such as cancer detection, treatment selection, and monitoring of treatment response or disease progression. Its work is intended to complement conventional tissue-based testing by providing less-invasive access to tumor information.

The company is headquartered in Israel and serves the global biopharmaceutical and clinical research markets. Publicly available information about its product portfolio, commercial reach, and leadership team remains limited.

View ImageneBio Profile